|
1.
|
Epstein MA, Achong BG and Barr YM: Virus
particles in cultured lymphoblasts from Burkitt’s lymphoma. Lancet.
1:702–703. 1964.PubMed/NCBI
|
|
2.
|
Kieff ED and Rickinson AB: Epstein-Barr
virus and its replication. Fields’ virology. Knipe DM and Howley
PM: Lippincott Williams & Wilkins; Philadelphia: pp. 2603–2654.
2006
|
|
3.
|
Taylor GS and Blackbourn DJ: Infectious
agents in human cancers: lessons in immunity and immunomodulation
from gammaherpesviruses EBV and KSHV. Cancer Lett. 305:263–278.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Kaye KM, Izumi KM and Kieff E:
Epstein-Barr virus latent membrane protein 1 is essential for
B-lymphocyte growth transformation. Proc Natl Acad Sci USA.
90:9150–9154. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Devergne O, Cahir McFarland ED, Mosialos
G, Izumi KM, Ware CF and Kieff E: Role of the TRAF binding site and
NF-κB activation in Epstein-Barr virus latent membrane protein
1-induced cell gene expression. J Virol. 72:7900–7908. 1998.
|
|
6.
|
Izumi KM and Kieff ED: The Epstein-Barr
virus oncogene product latent membrane protein 1 engages the tumor
necrosis factor receptor-associated death domain protein to mediate
B lymphocyte growth transformation and activate NF-κB. Proc Natl
Acad Sci USA. 94:12592–12597. 1997.PubMed/NCBI
|
|
7.
|
Soni V, Cahir-McFarland E and Kieff E:
LMP1 TRAFficking activates growth and survival pathways. Adv Exp
Med Biol. 597:173–187. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Schultheiss U, Püschner S, Kremmer E, Mak
TW, Engelmann H, Hammerschmidt W and Kieser A: TRAF6 is a critical
mediator of signal transduction by the viral oncogene latent
membrane protein 1. EMBO J. 20:5678–5691. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Hayden MS and Ghosh S: Shared principles
in NF-κB signaling. Cell. 132:344–362. 2008.
|
|
10.
|
Zandi E and Karin M: Bridging the gap:
composition, regulation, and physiological function of the IκB
kinase complex. Mol Cell Biol. 19:4547–4551. 1999.PubMed/NCBI
|
|
11.
|
Woronicz JD, Gao X, Cao Z, Rothe M and
Goeddel DV: IκB kinase-β: NF-κB activation and complex formation
with IκB kinase-α and NIK. Science. 278:866–869. 1997.
|
|
12.
|
Lee FS, Peters RT, Dang LC and Maniatis T:
MEKK1 activates both IκB kinase α and IκB kinase β. Proc Natl Acad
Sci USA. 95:9319–9324. 1998.
|
|
13.
|
Sylla BS, Hung SC, Davidson DM,
Hatzivassiliou E, Malinin NL, Wallach D, Gilmore TD, Kieff E and
Mosialos G: Epstein-Barr virus-transforming protein latent
infection membrane protein 1 activates transcription factor NF-κB
through a pathway that includes the NF-κB-inducing kinase and the
IκB kinases IKKα and IKKβ. Proc Natl Acad Sci USA. 95:10106–10111.
1998.PubMed/NCBI
|
|
14.
|
Sánchez-Mateos P and Sánchez-Madrid F:
Structure-function relationship and immunochemical mapping of
external and intracellular antigenic sites on the lymphocyte
activation inducer molecule, AIM/CD69. Eur J Immunol. 21:2317–2325.
1991.
|
|
15.
|
Sant’Angelo DB, Lucas B, Waterbury PG,
Cohen B, Brabb T, Goverman J, Germain RN and Janeway CA Jr: A
molecular map of T cell development. Immunity. 9:179–186. 1998.
|
|
16.
|
Testi R, D’Ambrosio D, De Maria R and
Santoni A: The CD69 receptor: a multipurpose cell-surface trigger
for hematopoietic cells. Immunol Today. 15:479–483. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
De la Fuente H, Cibrián D and
Sánchez-Madrid F: Immunoregulatory molecules are master regulators
of inflammation during the immune response. FEBS Lett.
586:2897–2905. 2012.PubMed/NCBI
|
|
18.
|
Huen DS, Henderson SA, Croom-Carter D and
Rowe M: The Epstein-Barr virus latent membrane protein-1 (LMP1)
mediates activation of NF-κB and cell surface phenotype via two
effector regions in its carboxy-terminal cytoplasmic domain.
Oncogene. 10:549–560. 1995.
|
|
19.
|
Floettmann JE and Rowe M: Epstein-Barr
virus latent membrane protein-1 (LMP1) C-terminus activation region
2 (CTAR2) maps to the far C-terminus and requires oligomerisation
for NF-κB activation. Oncogene. 15:1851–1858. 1997.PubMed/NCBI
|
|
20.
|
López-Cabrera M, Muñoz E, Blázquez MV,
Ursa MA, Santis AG and Sánchez-Madrid F: Transcriptional regulation
of the gene encoding the human C-type lectin leukocyte receptor
AIM/CD69 and functional characterization of its tumor necrosis
factor-α-responsive elements. J Biol Chem. 270:21545–21551.
1995.PubMed/NCBI
|
|
21.
|
Castellanos Mdel C, López-Giral S,
López-Cabrera M and de Landázuri MO: Multiple cis-acting elements
regulate the expression of the early T cell activation antigen
CD69. Eur J Immunol. 32:3108–3117. 2002.PubMed/NCBI
|
|
22.
|
Brockman JA, Scherer DC, McKinsey TA, Hall
SM, Qi X, Lee WY and Ballard DW: Coupling of a signal response
domain in IκBα to multiple pathways for NF-κB activation. Mol Cell
Biol. 15:2809–2818. 1995.
|
|
23.
|
McKinsey TA, Brockman JA, Scherer DC,
Al-Murrani SW, Green PL and Ballard DW: Inactivation of IκBβ by the
Tax protein of human T-cell leukemia virus type 1: a potential
mechanism for constitutive induction of NF-κB. Mol Cell Biol.
16:2083–2090. 1996.
|
|
24.
|
Geleziunas R, Ferrell S, Lin X, Mu Y,
Cunningham ET Jr, Grant M, Connelly MA, Hambor JE, Marcu KB and
Greene WC: Human T-cell leukemia virus type 1 Tax induction of
NF-κB involves activation of the IκB kinase α (IKKα) and IKKβ
cellular kinases. Mol Cell Biol. 18:5157–5165. 1998.
|
|
25.
|
Iha H, Kibler KV, Yedavalli VRK,
Peloponese JM, Haller K, Miyazato A, Kasai T and Jeang K-T:
Segregation of NF-κB activation through NEMO/IKKγ by Tax and TNFα:
implications for stimulus-specific interruption of oncogenic
signaling. Oncogene. 22:8912–8923. 2003.
|
|
26.
|
Muzio M, Ni J, Feng P and Dixit VM: IRAK
(Pelle) family member IRAK-2 and MyD88 as proximal mediators of
IL-1 signaling. Science. 278:1612–1615. 1997. View Article : Google Scholar
|
|
27.
|
Aizawa S, Nakano H, Ishida T, Horie R,
Nagai M, Ito K, Yagita H, Okumura K, Inoue J and Watanabe T: Tumor
necrosis factor receptor associated factor (TRAF) 5 and TRAF2 are
involved in CD30-mediated NFκB activation. J Biol Chem.
272:2042–2045. 1997.PubMed/NCBI
|
|
28.
|
Antalis TM and Godbolt D: Isolation of
intact nuclei from hematopoietic cell types. Nucl Acids Res.
19:43011991. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Dewan MZ, Tomita M, Katano H and Yamamoto
N, Ahmed S, Yamamoto M, Sata T, Mori N and Yamamoto N: An HIV
protease inhibitor, ritonavir targets the nuclear factor-kappaB and
inhibits the tumor growth and infiltration of EBV-positive
lymphoblastoid B cells. Int J Cancer. 124:622–629. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Xu Z-G, Iwatsuki K, Oyama N, Ohtsuka M,
Satoh M, Kikuchi S, Akiba H and Kaneko F: The latency pattern of
Epstein-Barr virus infection and viral IL-10 expression in
cutaneous natural killer/T-cell lymphomas. Br J Cancer. 84:920–925.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Baeuerle PA: The inducible transcription
activator NF-κB: regulation by distinct protein subunits. Biochim
Biophys Acta. 1072:63–80. 1991.
|
|
32.
|
Hodge G, Hodge S, Han P and Haslam R:
Multiple leucocyte activation markers to detect neonatal infection.
Clin Exp Immunol. 135:125–129. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Böhler T, Walcher J, Hölzl-Wenig G,
Schnitzler P, Geiss M, Buchholz B, Linde R, Rütschle H and Debatin
K-M: Expression of CD69 on T-cells from HIV-1-infected children and
adolescents increases with increasing viral load. Eur J Pediatr.
158:638–644. 1999.PubMed/NCBI
|
|
34.
|
Iwashiro M, Messer RJ, Peterson KE,
Stromnes IM, Sugie T and Hasenkrug KJ: Immunosuppression by
CD4+ regulatory T cells induced by chronic retroviral
infection. Proc Natl Acad Sci USA. 98:9226–9230. 2001.
|
|
35.
|
Vega-Ramos J, Alari-Pahissa E, Valle JD,
Carrasco-Marín E, Esplugues E, Borràs M, Martínez-A C and Lauzurica
P: CD69 limits early inflammatory diseases associated with immune
response to Listeria monocytogenes infection. Immunol Cell
Biol. 88:707–715. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Esplugues E, Sancho D, Vega-Ramos J,
Martínez C, Syrbe U, Hamann A, Engel P, Sánchez-Madrid F and
Lauzurica P: Enhanced antitumor immunity in mice deficient in CD69.
J Exp Med. 197:1093–1106. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Sancho D, Gómez M, Viedma F, Esplugues E,
Gordón-Alonso M, García-López MA, de la Fuente H, Martínez-A C,
Lauzurica P and Sánchez-Madrid F: CD69 downregulates autoimmune
reactivity through active transforming growth factor-β production
in collagen-induced arthritis. J Clin Invest. 112:872–882.
2003.PubMed/NCBI
|
|
38.
|
Zhao Q, Kuang D-M, Wu Y, Xiao X, Li X-F,
Li T-J and Zheng L: Activated CD69+ T cells foster
immune privilege by regulating IDO expression in tumor-associated
macrophages. J Immunol. 188:1117–1124. 2012.
|
